March Altus Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

March Altus Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$2.04M	Hold	218,515	–	–	12.79%	3
2016 Q2	$1.38M	Hold	218,515	–	–	10.67%	6
2016 Q1	$1.21M	Hold	218,515	–	–	12.48%	4
2015 Q4	$1.22M	Buy	218,515 +107,978	+98%	+$714K	11.21%	5
2015 Q3	$935K	Buy	+110,537	New	+$1.87M	5.51%	5

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

March Altus Capital Management's PETX Position: Q3 2016 in Review

March Altus Capital Management held its Aratana Therapeutics, Inc. (PETX) position steady in Q3 2016 at 218,515 shares worth $2.04M. The position accounts for 12.79% of the portfolio, ranked #3.

March Altus Capital Management first reported a position in PETX in Q3 2015 and has held it in 5 quarters since. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

March Altus Capital Management held 218,515 shares of Aratana Therapeutics, Inc. worth $2.04M as of Q3 2016.
March Altus Capital Management left its Aratana Therapeutics, Inc. share count unchanged in Q3 2016.
Aratana Therapeutics, Inc. made up 12.79% of March Altus Capital Management's portfolio in Q3 2016, its #3 holding.
March Altus Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and has held it in 5 quarters since.
128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on March Altus Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.